Abstract Library

#2895 Survival Related to Treatment of Patients with Metastatic Neuroendocrine Lung Tumors Treated in a Brazilian Center

Introduction: Well-differentiated Neuroendocrine Pulmonary Tumors (NETp) are morphologically classified as Typical (TC) and Atypical Carcinoid (AC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tanaka H

Authors: Tanaka H, Petrocchi Corassa M, Carioca Freitas H, José de Barros e Silva M, Riechelmann R,

Keywords: Atypical Carcinoid, Typical Carcinoid, Neuroendocrine Pulmonary Tumors,

#2817 METNET: A Phase II Trial of Metformin in Patients with Well Differentiated Neuroendocrine Tumors

Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Glasberg J

Authors: Glasberg J, Talans A, Lopez R, Recchimuzzi D, Riechelmann R,

Keywords: neuroendocrine tumors, metformin, clinical trial,

#2691 Somatostatin Analogs in Patients with Zollinger Ellison Syndrome (ZES): An Observational Study

Introduction: Zollinger Ellison syndrome (ZES) is a rare syndrome caused by gastrin hypersecretion from a primary neuroendocrine tumor (NET), usually located within the duodenum or into the pancreas. Gastrinomas have two important treatment goal: the control of the gastrin-excess state and the control of tumor growth.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: massironi s

Authors: Massironi S, Peracchi M, Elvevi A, Cristoferi L, Quatrini M,

Keywords: ZES, gastrinoma, somatostatin analogs,

#1412 MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease

Introduction: This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Giandomenico V

Authors: Giandomenico V, Li S, Lind T, Boccherini M, Skogseid B,

Keywords: glycolytic metabolism, peptide receptor radionuclide therapy (PRRT), serum samples, miRNA, FDG-PET positive and-PET negative SI-NET patients,

#1344 Reassessment of Proliferative Activity at Disease Progression in Neuroendocrine Neoplasms

Introduction: Ki67 is a key factor influencing prognosis and treatment in NENs. However, whether repeating histology at time of progression of disease (PD) is debated

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Cicchese N

Authors: Cicchese N, Panzuto F, Rinzivillo M, Capurso G, Merola E,

Keywords: Ki-67, tumor progression,